Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ GRB2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA110033
Description
This antibody recognizes Grb2, a highly conserved approximately 26 kDa intracellular adaptor protein. The immunogen has 100% identity between man, cow, rat and mouse. Western Blot: Reducing conditions.
GRB 2 protein contains one SH2 domain flanked on both sides by an SH3 domain. In response to EGF, GRB 2 binds, through its SH3 domains, to the guanine nucleotide exchange factor, Sos. The GRB 2-Sos complex then binds the EGF receptor. These interactions play a critical role in the activation of the p21 ras signaling pathway.
Specifications
GRB2 | |
Polyclonal | |
Unconjugated | |
GRB2 | |
AA408164; abundant SRC homology; adapter protein GRB2; Adapter protein GRB2-A; ASH; ASH protein; EGFRBP-GRB2; epidermal growth factor receptor-binding protein GRB2; grb2; grb2.L; grb2-a; grb2-b; Grb3-3; growth factor receptor bound protein 2; growth factor receptor bound protein 2 L homeolog; growth factor receptor-bound protein 2; Growth factor receptor-bound protein 2-A; growth factor receptor-bound protein 3; HT027; hypothetical protein LOC535298; MST084; MSTP084; NCKAP2; OTTHUMP00000166097; OTTHUMP00000166098; protein Ash; SH2/SH3 adapter GRB2; SH2/SH3 adapter GRB2-A; SH2/SH3 adaptor Grb2; XELAEV_18044055mg | |
Rabbit | |
Affinity Chromatography | |
RUO | |
2885 | |
4°C, do not freeze | |
Liquid |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 0.2% BSA and 15mM sodium azide; pH 7.4 | |
P62993 | |
GRB2 | |
Synthetic peptide corresponding to C-terminus of human Grb2 (amino acids 198-217). | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction